ProCE Banner Activity

KEYNOTE-522: Exploratory Analysis of EFS by Residual Cancer Burden With Neoadjuvant Pembrolizumab + Chemotherapy for Early TNBC

Slideset Download
Conference Coverage
Compared with placebo, pembrolizumab added to neoadjuvant chemotherapy was associated with lower residual cancer burden in patients with TNBC and with prolonged EFS even in patients without a pCR.

Released: June 14, 2022

Expiration: June 13, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab